Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II randomized double-blind active-controlled study of an inactivated tetravalent enterovirus vaccine in healthy participants aged 6 months and older
CTR20262747Phase 2Active
- Sponsor
- Beijing Minhai Biological
- Start
- Jul 2026
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tetravalent enterovirus vaccine (vero cell), inactivated in herpangina, sponsored by Beijing Minhai Biological. Started Jul 2026; status: active.
02
Drugs
tetravalent enterovirus vaccine (vero cell), inactivated
03
Conditions
herpangina
Beyond the preview
Go deeper on CTR20262747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262747.